Selected research
Industry Research
Attenuated Vaccine Industry Research Report 2026
Market perspective
The global Attenuated Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Attenuated Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Attenuated Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Attenuated Vaccine include Changchun BCHT Biotechnology Co.,Ltd, Shanghai Rongsheng Biotech, Sanofi, Johnson & Johnson, Merck & Co., Pfizer Inc, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd. and Green Cross Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Attenuated Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Attenuated Vaccine Market by Company
Changchun BCHT Biotechnology Co.,Ltd
Shanghai Rongsheng Biotech
Sanofi
Johnson & Johnson
Merck & Co.
Pfizer Inc
GlaxoSmithKline plc
Serum Institute of India Pvt. Ltd.
Green Cross Corporation
CSL Limited
Biken
Astellas Pharma
Attenuated Vaccine Segment by Type
Bacterial Vaccine
Viral Vaccine
Attenuated Vaccine Segment by Application
Hospital
Clinic
Others
Attenuated Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Attenuated Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Attenuated Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Attenuated Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bacterial Vaccine
- Viral Vaccine
Applications
- Hospital
- Clinic
- Others
Companies covered
- Changchun BCHT Biotechnology Co.,Ltd
- Shanghai Rongsheng Biotech
- Sanofi
- Johnson & Johnson
- Merck & Co.
- Pfizer Inc
- GlaxoSmithKline plc
- Serum Institute of India Pvt. Ltd.
- Green Cross Corporation
- CSL Limited
- Biken
- Astellas Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Attenuated Vaccine Market Size (2021-2032)
- 2.2.2 Global Attenuated Vaccine Sales (2021-2032)
- 2.2.3 Global Attenuated Vaccine Market Average Price (2021-2032)
- 2.3 Attenuated Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Bacterial Vaccine
- 2.3.3 Viral Vaccine
- 2.4 Attenuated Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Attenuated Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Attenuated Vaccine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Attenuated Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Attenuated Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Attenuated Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Attenuated Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Attenuated Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Attenuated Vaccine, Established Date
- 3.9 Global Attenuated Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Changchun BCHT Biotechnology Co.,Ltd
- 4.1.1 Changchun BCHT Biotechnology Co.,Ltd Company Information
- 4.1.2 Changchun BCHT Biotechnology Co.,Ltd Business Overview
- 4.1.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio
- 4.1.5 Changchun BCHT Biotechnology Co.,Ltd Recent Developments
- 4.2 Shanghai Rongsheng Biotech
- 4.2.1 Shanghai Rongsheng Biotech Company Information
- 4.2.2 Shanghai Rongsheng Biotech Business Overview
- 4.2.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio
- 4.2.5 Shanghai Rongsheng Biotech Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Attenuated Vaccine Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Johnson & Johnson
- 4.4.1 Johnson & Johnson Company Information
- 4.4.2 Johnson & Johnson Business Overview
- 4.4.3 Johnson & Johnson Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Johnson & Johnson Attenuated Vaccine Product Portfolio
- 4.4.5 Johnson & Johnson Recent Developments
- 4.5 Merck & Co.
- 4.5.1 Merck & Co. Company Information
- 4.5.2 Merck & Co. Business Overview
- 4.5.3 Merck & Co. Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck & Co. Attenuated Vaccine Product Portfolio
- 4.5.5 Merck & Co. Recent Developments
- 4.6 Pfizer Inc
- 4.6.1 Pfizer Inc Company Information
- 4.6.2 Pfizer Inc Business Overview
- 4.6.3 Pfizer Inc Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Inc Attenuated Vaccine Product Portfolio
- 4.6.5 Pfizer Inc Recent Developments
- 4.7 GlaxoSmithKline plc
- 4.7.1 GlaxoSmithKline plc Company Information
- 4.7.2 GlaxoSmithKline plc Business Overview
- 4.7.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline plc Attenuated Vaccine Product Portfolio
- 4.7.5 GlaxoSmithKline plc Recent Developments
- 4.8 Serum Institute of India Pvt. Ltd.
- 4.8.1 Serum Institute of India Pvt. Ltd. Company Information
- 4.8.2 Serum Institute of India Pvt. Ltd. Business Overview
- 4.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio
- 4.8.5 Serum Institute of India Pvt. Ltd. Recent Developments
- 4.9 Green Cross Corporation
- 4.9.1 Green Cross Corporation Company Information
- 4.9.2 Green Cross Corporation Business Overview
- 4.9.3 Green Cross Corporation Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Green Cross Corporation Attenuated Vaccine Product Portfolio
- 4.9.5 Green Cross Corporation Recent Developments
- 4.10 CSL Limited
- 4.10.1 CSL Limited Company Information
- 4.10.2 CSL Limited Business Overview
- 4.10.3 CSL Limited Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CSL Limited Attenuated Vaccine Product Portfolio
- 4.10.5 CSL Limited Recent Developments
- 4.11 Biken
- 4.11.1 Biken Company Information
- 4.11.2 Biken Business Overview
- 4.11.3 Biken Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Biken Attenuated Vaccine Product Portfolio
- 4.11.5 Biken Recent Developments
- 4.12 Astellas Pharma
- 4.12.1 Astellas Pharma Company Information
- 4.12.2 Astellas Pharma Business Overview
- 4.12.3 Astellas Pharma Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Astellas Pharma Attenuated Vaccine Product Portfolio
- 4.12.5 Astellas Pharma Recent Developments
5 Global Attenuated Vaccine Market Scenario by Region
- 5.1 Global Attenuated Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Attenuated Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Attenuated Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Attenuated Vaccine Sales by Region: 2027-2032
- 5.3 Global Attenuated Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Attenuated Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Attenuated Vaccine Revenue by Region: 2027-2032
- 5.4 North America Attenuated Vaccine Market Facts & Figures by Country
- 5.4.1 North America Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Attenuated Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Attenuated Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Attenuated Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Attenuated Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Attenuated Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Attenuated Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Attenuated Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Attenuated Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Attenuated Vaccine Market Facts & Figures by Country
- 5.7.1 South America Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Attenuated Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Attenuated Vaccine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Attenuated Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Attenuated Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Attenuated Vaccine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Attenuated Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Attenuated Vaccine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Attenuated Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Attenuated Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Attenuated Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Attenuated Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Attenuated Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Attenuated Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Attenuated Vaccine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Attenuated Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Attenuated Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Attenuated Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Attenuated Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Attenuated Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Attenuated Vaccine Value Chain Analysis
- 8.1.1 Attenuated Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Attenuated Vaccine Production Mode & Process
- 8.2 Attenuated Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Attenuated Vaccine Distributors
- 8.2.3 Attenuated Vaccine Customers
9 Global Attenuated Vaccine Analyzing Market Dynamics
- 9.1 Attenuated Vaccine Industry Trends
- 9.2 Attenuated Vaccine Industry Drivers
- 9.3 Attenuated Vaccine Industry Opportunities and Challenges
- 9.4 Attenuated Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst